The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor

Annals of the Rheumatic Diseases

Volumn 74, Issue 2, 2015, Pages 430-436

  Harrold, Leslie R ^a   Reed, George W ^a   Kremer, Joel M ^b   Curtis, Jeffrey R ^c   Solomon, Daniel H ^d   Hochberg, Marc C ^e   Greenberg, Jeffrey D ^f  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; PREDNISONE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR;

ADULT; AMERICAN COLLEGE OF RHEUMATOLOGY; ARTICLE; ASSESSMENT OF HUMANS; CLINICAL DISEASE ACTIVITY INDEX; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; UNITED STATES; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; MIDDLE AGED;

ABATACEPT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84921355050     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203936     Document Type: Article

References (32)

1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25.
2. Smolen JS, Aletaha D, Machold KP. Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005;19:163-77.
3. van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009;374:459-66.
4. Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007;56:1417-23.
5. Gomez-Reino JJ, Maneiro JR, Ruiz J, et al. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. Ann Rheum Dis 2012;71:1861-4.
6. Kekow J, Mueller-Ladner U, Schulze-Koops H. Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNF-alpha blocker failure. Biologics: Targets Ther 2012;6:191-9.
7. Blom M, Kievit W, Donders AR, et al. Effectiveness of a third tumor necrosis factor-alpha-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis. J Rheumatol 2011;38:2355-61.
8. Salliot C, Finckh A, Katchamart W, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011;70:266-71.
9. Guyot P, Taylor P, Christensen R, et al. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res Ther 2011;13:R204.
10. Guyot P, Taylor PC, Christensen R, et al. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom. J Rheumatol 2012;39:1198-206.
11. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
12. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15.
13. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76.
14. Schiff M, Weinblatt M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73:86-94.
15. Siegel J. Comparative effectiveness of treatments for rheumatoid arthritis. Ann Intern Med 2008;148:162-3.
16. Greenberg JD, Bingham CO 3rd, Abramson SB, et al. Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. Arthritis Rheum 2005;53:12-17.
17. Kremer J. The CORRONA database. Ann Rheum Dis 2005;64(Suppl 4):iv37-41.
18. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
19. Aletaha D, Nell VPK, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806.
20. Greenberg JD, Harrold LR, Bentley MJ, et al. Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis. Rheumatology (Oxford) 2009;48:686-90.
21. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
22. Goldman JA, Xia HA, White B, et al. Evaluation of a modified ACR20 scoring system in patients with rheumatoid arthritis receiving treatment with etanercept. Ann Rheum Dis 2006;65:1649-52.
23. Maska L, Anderson J, Michaud K. Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL). Arthritis Care Res 2011;63(S11):S4-13.
24. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
25. Bentley MJ, Greenberg JD, Reed GW. A modified rheumatoid arthritis disease activity score without acute-phase reactants (mDAS28) for epidemiological research. J Rheumatol 2010;37:1607-14.
26. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 2008;27:2037-49.
27. Rassen JA, Shelat AA, Myers J, et al. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf 2012;21(Suppl 2):69-80.
28. Guyot P, Taylor PC, Christensen RP, et al. Indirect Treatment Comparison of Abatacept with Methotrexate Versus Other Biologic Agents for Active Rheumatoid Arthritis Despite Methotrexate Therapy in the United Kingdom. J Rheumatol 2012;39:1198-206.
29. Hochberg MC, Berry S, Broglio K, et al. Mixed treatment comparison of efficacy and tolerability of biologic agents in patients with rheumatoid arthritis. Curr Med Res Opin 2013;29:1213-22.
30. Yazici Y, Filopoulos MT, Swearingen CJ. Comparative Effectiveness and Time to Response Among Abatacept, Adalimumab, Etanercept and Infliximab for the Treatment of Rheumatoid Arthritis in a Real World Routine Care Registry. [abstract]. Arthritis Rheum 2011;63(Suppl 10):2233.
31. Yazici Y, Swearingen C, Nadkarni A, et al. Comparative Efficacy and Tolerability of Biologic Therapies in Early Rheumatoid Arthritis Utilizing a Bayesian Approach. [abstract]. Arthritis Rheum 2011;63(Suppl 10):1240.
32. Greenberg JD, Kishimoto M, Strand V, et al. Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort. Am J Med 2008;121:532-8.